CD274 and neoplasm: Previously, we have reported superior antagonistic activity of bsAbs towards cancer cells that co-overexpress a tumor-associated antigen of interest and immune checkpoints PD-L1 [19,20] or CD47 [21,22], which was most likely attributable to the enhanced avidity associated with the tetravalent bsAb-format.